Kevin Dondarskit of Deloitte Consulting discusses how pharma companies are focusing on high-value assets that serve large patient populations.
Kevin Dondarski
Advertisement
Kevin Dondarski is a partner at Deloitte Consulting, life sciences strategy practice.
Articles by Kevin Dondarski
Kevin Dondarski from Deloitte Consulting discusses how changes in industry trends are causing pharma companies to explore new market opportunities provided by the rise of GLP-1 medications.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Biotech Industry’s Relationship with Real-Time Data: Q&A with Dr. Richard Graham
2
Does FDA's Shift From Two Pivotal Trials to One Represent a Genuine Evolution?
3
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
4
Pharmaceutical Executive Daily: FDA Approves Datroway
5